



FOR IMMEDIATE RELEASE

BIOSYENT SUBSIDIARY HTI AGRITECH INC. CHANGES NAME TO HEDLEY TECHNOLOGIES LTD.

MISSISSAUGA, ONTARIO (June 13, 2006) BioSyent Inc. ("BioSyent", TSX Venture: RX) announced at today's Annual General Meeting that effective immediately its wholly owned subsidiary HTI Agritech Inc., owner and operator of BioSyent's bio and health friendly non-chemical insecticide business, has changed its name to Hedley Technologies Ltd. ("Hedley").

Hedley will continue to market Protect-It® stored grain insecticide and Insecolo™ home and garden insecticide to customers in Canada, the U.S. and abroad.

The BioSyent Board of Directors also announced that Douglas Larson has resigned as President and Chief Operating Officer of BioSyent Inc. Mr. Larson will remain as a Member of the Board of Directors of BioSyent and will continue as President and Chief Operating Officer of subsidiary Hedley Technologies Ltd. René Goehrum has assumed Mr. Larson's BioSyent operating responsibilities and is now Chairman, President and CEO of BioSyent Inc.

BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

For additional information contact:

René C. Goehrum, Chairman, President and CEO

rgoehrum@biosyent.com

Tel: (905) 206-0013

www.biosyent.com

Fax: (905) 206-1413

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.